益肾疏肝理气方在乳腺浸润癌中的潜在治疗机制:基于网络药理学的研究  

A study on the mechanism of action of yishen shugan liqi formula in invasive breast cancer based on network pharmacology

作　　者：张科 赵玉涵 王丹丹 冯艳虹 张嵩 ZHANG Ke;ZHAO Yuhan;WANG Dandan;FENG Yanhong;ZHANG Song(Hebei Tangshan Traditional Chinese Medicine Hospital,Tangshan O63000;Affiliated Hospital of North China University of Science and Technology,Tangshan 063000,China)

机构地区：[1]河北省唐山市中医医院,河北省唐山市063000 [2]华北理工大学附属医院,河北省唐山市063000

出　　处：《中国煤炭工业医学杂志》2025年第1期8-17,共10页Chinese Journal of Coal Industry Medicine

基　　金：河北省中医药管理局科研计划项目(编号:2024432)。

摘　　要：目的通过网络药理学和生物信息学手段,研究益肾疏肝理气方在乳腺浸润癌(IBC)中的潜在治疗机制及关键靶点。方法首先通过TCGA(The Cancer Genome Atlas)数据库筛选IBC癌症和癌旁组织的差异表达基因并进行预后相关基因分析。通过蛋白质-蛋白质相互作用网络(PPI)分析筛选核心(Hub)基因,并通过Coremine、TCMSP等数据库对益肾疏肝理气方的活性成分进行筛选及靶向基因预测。然后,结合筛选结果,分析相关基因在IBC中的表达差异及其与免疫细胞浸润的相关性。最后,采用分子对接技术分析NR3C2与益肾疏肝理气方中的主成分茯苓的相互作用。结果识别出490个差异表达的基因,并通过PPI网络分析筛选出多个潜在的Hub基因。通过网络药理学分析,茯苓作为益肾疏肝理气方中的核心成分,其相关活性小分子对IBC具有潜在的靶向作用。进一步的研究显示,NR3C2在IBC组织中显著下调,并与免疫细胞的浸润密切相关。NR3C2的高表达与更好的预后相关(P<0.05)。分子对接结果表明,NR3C2与茯苓中的7种小分子具有良好的结合能力。结论NR3C2可能作为IBC治疗的新靶点,其与茯苓的主要成分具有潜在的靶向关系,为益肾疏肝理气方在IBC治疗中的应用提供了理论依据。此外,NR3C2的免疫调节作用也为乳腺癌免疫治疗提供了新的研究方向。Objective To explore the potential therapeutic mechanisms and key targets of Yishen Shugan Liqi Decoction in Invasive Breast Cancer(IBC)through network pharmacology and bioinformatics approaches.Methods First,differential expression genes(DEGs)in IBC cancer and adjacent tissues were screened from the TCGA(The Cancer Genome Atlas)database,followed by prognostic gene analysis.Core(Hub)genes were identified through Protein-Protein Interaction(PPI)network analysis,and the active components of Yishen Shugan Liqi Decoction were selected and target genes predicted using databases such as Coremine and TCMSP.Then,the expression differences of the related genes in IBC and their correlation with immune cell infiltration were analyzed.Finally,molecular docking technology was used to analyze the interaction between NR3C2 and Fuling,the main component of Yishen Shugan Liqi Decoction.Results A total of 490 DEGs were identified,and several potential Hub genes were screened through PPI network analysis.Network pharmacology analysis indicated that Poria,as a core component of YSLF,possesses active small molecules with potential targeting effects on IBC.Further studies revealed that NR3C2 is significantly downregulated in IBC tssues and is closely associated with immune cell infiltration.High expression of NR3C2 correlates with better prognosis(P<0.05).Molecular docking showed that NR3C2 has good binding affinity with seven small molecules from Poria.Conclusion NR3C2 may serve as a novel therapeutic target for IBC,with a potential targeting relationship to the primary components of Poria,providing theoretical support for the application of YSLF in IBC treatment.Additionally,the immunomodulatory role of NR3C2 offers a new research direction for breast cancer immunotherapy.

关 键 词：浸润性乳腺癌 NR3C2 益肾疏肝理气方 网络药理学 分子对接 免疫细胞浸润 

分 类 号：R737.9[医药卫生—肿瘤]